Beta-catenin expression is prognostic of improved non-small cell lung cancer survival

Connie G Chiu; Simon K Chan; Z Amy Fang; Hamid Masoudi; Richard Wood-Baker; Steven J M Jones; Blake Gilks; Janessa Laskin; Sam M Wiseman

doi:10.1016/j.amjsurg.2012.01.002

Beta-catenin expression is prognostic of improved non-small cell lung cancer survival

Am J Surg. 2012 May;203(5):654-659. doi: 10.1016/j.amjsurg.2012.01.002. Epub 2012 Mar 7.

Authors

Connie G Chiu¹, Simon K Chan², Z Amy Fang³, Hamid Masoudi⁴, Richard Wood-Baker⁵, Steven J M Jones², Blake Gilks⁶, Janessa Laskin⁷, Sam M Wiseman⁸

Affiliations

¹ Department of Surgery, St. Paul's Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.
² Department of Medical Genetics, University of British Columbia and Michael Smith Genome Sciences Center, British Columbia Cancer Research Center, Vancouver, BC, Canada.
³ Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
⁵ Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada; Menzies Research Institute, Tasmania, Hobart, Tasmania, Australia.
⁶ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada.
⁷ Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
⁸ Department of Surgery, St. Paul's Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Electronic address: smwiseman@providencehealth.bc.ca.

PMID: 22402266
DOI: 10.1016/j.amjsurg.2012.01.002

Abstract

Introduction: The objectives of this study were to determine the frequency and prognostic significance of beta-catenin expression in a cohort of non-small cell lung cancer (NSCLC) patients.

Methods: Tissue microarrays were constructed using clinically annotated formalin-fixed paraffin-embedded tumor samples from individuals diagnosed with NSCLC who underwent surgical resection with curative intent and had beta-catenin expression status determined by immunohistochemistry.

Results: Negative beta-catenin expression was seen in 28% (103/370) of NSCLC cases and was prognostic of a reduced overall patient survival (P = .008) and also was significantly correlated with the presence of lymphatic invasion (P = .015). In multivariate analysis, the loss of beta-catenin expression retained independent prognostic significance and showed an adjusted hazard ratio of 3.18 (confidence interval, 1.46-6.91, P = .004) for reduced patient survival when adjusting for the presence of lymphatic invasion, tumor grade, nodal status, and tumor stage.

Conclusions: Beta-catenin represents an important prognostic marker in individuals diagnosed with surgically resectable NSCLC.

MeSH terms

Aged
Carcinoma, Non-Small-Cell Lung / metabolism*
Carcinoma, Non-Small-Cell Lung / mortality*
Female
Humans
Lung Neoplasms / metabolism*
Lung Neoplasms / mortality*
Male
Middle Aged
Prognosis
Survival Analysis
beta Catenin / biosynthesis*

Substances

beta Catenin